INTRODUCTION: Ulcerated melanomas may have a unique biology and microenvironment. We test whether markers of immune infiltration correlate with clinical outcome in ulcerated compared to non-ulcerated primary melanoma tumors. METHODS: Sixty-two stage II-III cutaneous melanomas, 32 ulcerated and 30 non-ulcerated, were analyzed for tumor-infiltrating lymphocytes (TILs). Immunohistochemistry (IHC) was performed for CD2, a marker previously shown to correlate with overall survival (OS) and recurrence-free survival (RFS) in this patient population. IHC using antibody, VE1, to BRAF V600E was also performed on a subset of 41 tumors to assess the relationship of BRAF mutation to immune markers. RESULTS: We found, using Cox regression models, that the presence of TILs was associated with improved OS (p = 0.034) and RFS (p = 0.002) in ulcerated melanoma tumors, but not in non-ulcerated melanoma (p = 0.632, 0.416). CD2 expression also was correlated with improved OS (p = 0.021) and RFS (p = 0.001) in ulcerated melanoma, but no relationship was seen in non-ulcerated melanoma (p = 0.427, 0.682). In this small population, BRAF status did not correlate with TILs or CD2+ count. CONCLUSION: Our data show that immune markers including TILs and CD2 count correlate more closely with survival in ulcerated melanomas than that in non-ulcerated melanomas. We propose that immune biomarkers may be particularly relevant to ulcerated, as compared to non-ulcerated, melanomas and that this merits study in larger populations.
INTRODUCTION:Ulcerated melanomas may have a unique biology and microenvironment. We test whether markers of immune infiltration correlate with clinical outcome in ulcerated compared to non-ulcerated primary melanoma tumors. METHODS: Sixty-two stage II-III cutaneous melanomas, 32 ulcerated and 30 non-ulcerated, were analyzed for tumor-infiltrating lymphocytes (TILs). Immunohistochemistry (IHC) was performed for CD2, a marker previously shown to correlate with overall survival (OS) and recurrence-free survival (RFS) in this patient population. IHC using antibody, VE1, to BRAFV600E was also performed on a subset of 41 tumors to assess the relationship of BRAF mutation to immune markers. RESULTS: We found, using Cox regression models, that the presence of TILs was associated with improved OS (p = 0.034) and RFS (p = 0.002) in ulcerated melanoma tumors, but not in non-ulcerated melanoma (p = 0.632, 0.416). CD2 expression also was correlated with improved OS (p = 0.021) and RFS (p = 0.001) in ulcerated melanoma, but no relationship was seen in non-ulcerated melanoma (p = 0.427, 0.682). In this small population, BRAF status did not correlate with TILs or CD2+ count. CONCLUSION: Our data show that immune markers including TILs and CD2 count correlate more closely with survival in ulcerated melanomas than that in non-ulcerated melanomas. We propose that immune biomarkers may be particularly relevant to ulcerated, as compared to non-ulcerated, melanomas and that this merits study in larger populations.
Authors: Kelly M McMasters; Michael J Edwards; Merrick I Ross; Douglas S Reintgen; Robert C G Martin; Marshall M Urist; R Dirk Noyes; Jeffrey J Sussman; Arnold J Stromberg; Charles R Scoggins Journal: Ann Surg Date: 2010-09 Impact factor: 12.969
Authors: Farhad Azimi; Richard A Scolyer; Pavlina Rumcheva; Marc Moncrieff; Rajmohan Murali; Stanley W McCarthy; Robyn P Saw; John F Thompson Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Alison L Burton; Brent A Roach; Michael P Mays; Andrea F Chen; Brooke A R Ginter; Abbey M Vierling; Charles R Scoggins; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters Journal: Am Surg Date: 2011-02 Impact factor: 0.688
Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan Journal: Science Date: 2015-03-12 Impact factor: 47.728
Authors: Dale Han; Jonathan S Zager; Yu Shyr; Heidi Chen; Lynne D Berry; Sanjana Iyengar; Mia Djulbegovic; Jaimie L Weber; Suroosh S Marzban; Vernon K Sondak; Jane L Messina; John T Vetto; Richard L White; Barbara Pockaj; Nicola Mozzillo; Kim James Charney; Eli Avisar; Robert Krouse; Mohammed Kashani-Sabet; Stanley P Leong Journal: J Clin Oncol Date: 2013-11-04 Impact factor: 44.544
Authors: M Mandalà; G L Imberti; D Piazzalunga; M Belfiglio; R Labianca; M Barberis; L Marchesi; P Poletti; L Bonomi; L Novellino; K Di Biagio; A Milesi; U Guerra; C Tondini Journal: Eur J Cancer Date: 2009-06-22 Impact factor: 9.162
Authors: Kara Rossfeld; Erinn M Hade; Alexandra Gangi; Matthew Perez; Emily N Kinsey; Joanna Grabska; Ashley Ederle; Jonathan Zager; April K Salama; Thomas E Olencki; Georgia M Beasley Journal: Int J Surg Oncol (N Y) Date: 2017-10-10